SCHEMBL1158028

SCHEMBL1158028

Cc1ccc(Nc2cc3cc[nH]c(=O)c3c(Nc3ccc(C4CCN(CC(N)=O)CC4)c(C)c3)n2)nc1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ZAP70 P43403 12/20 0.52
▸ FER P16591 1/20 0.43
▸ LYN P07948 3/20 0.37
▸ SRC P12931 2/20 0.37
▸ ALK Q9UM73 2/20 0.37
▸ BTK Q06187 1/20 0.36
▸ INSR P06213 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ SYK P43405 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ DRD4 P21917 2/20 0.36
▸ DRD2 P14416 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158483 0.86 ZAP70 (0.69) ZAP70FERLYNSRCBTK
SCHEMBL1158097 0.83 ZAP70 (0.62) ZAP70FERLYNBTKJAK2
SCHEMBL28790539 0.83 ZAP70 (0.75) ZAP70FERALKSYK
SCHEMBL1158225 0.80 ZAP70 (0.73) ZAP70FERALK
SCHEMBL1158035 0.80 ZAP70 (0.66) ZAP70FERLYNJAK2SYK
SCHEMBL12849064 0.80 ZAP70 (0.66) ZAP70FERLYNJAK2SYK
SCHEMBL1049667 0.79 ZAP70 (0.69) ZAP70JAK2
SCHEMBL1158473 0.79 ZAP70 (0.62) ZAP70FERLYNJAK2SYK
SCHEMBL1158629 0.79 ZAP70 (0.69) ZAP70FERLYNJAK2SYK
SCHEMBL1158565 0.76 ZAP70 (0.65) ZAP70FERLYNJAK2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 — — EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 — — EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 — — US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN ZAP70 5/4885FER 89/4885LYN 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback